128 related articles for article (PubMed ID: 35316861)
1. Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database.
Uchida M; Nakano K; Fujiwara M; Uesawa Y; Shimizu T
J Clin Pharm Ther; 2022 Aug; 47(8):1173-1180. PubMed ID: 35316861
[TBL] [Abstract][Full Text] [Related]
2. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
Nozawa M; Nonomura N; Ueda T; Nishimura K; Kanayama HO; Miki T; Nakatani T; Tomita Y; Azuma H; Yoshioka T; Tsujihata M; Uemura H
Jpn J Clin Oncol; 2013 Nov; 43(11):1132-8. PubMed ID: 23999768
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
Kanbayashi Y; Kobayashi M; Anzai M; Shimizu T; Uchida M
Oncology; 2023; 101(12):817-821. PubMed ID: 37591211
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.
Satoki A; Uchida M; Fujiwara M; Uesawa Y; Shimizu T
Oncology; 2022; 100(3):188-194. PubMed ID: 34915520
[TBL] [Abstract][Full Text] [Related]
6. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan.
Akaza H; Kurihara R; Katsura A; Harumiya M; Ushida N
Jpn J Clin Oncol; 2019 Oct; 49(10):956-964. PubMed ID: 31135920
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2022; 100(7):413-418. PubMed ID: 35504255
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.
Bono P; Oudard S; Bodrogi I; Hutson TE; Escudier B; Machiels JP; Thompson JA; Figlin RA; Ravaud A; Basaran M; Porta C; Bracarda S; Brechenmacher T; Lin C; Voi M; Grunwald V; Motzer RJ
Clin Genitourin Cancer; 2016 Oct; 14(5):406-414. PubMed ID: 27287020
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study.
Kawahara Y; Murata S; Shimizu T; Uesawa Y; Uchida M
In Vivo; 2023; 37(2):955-961. PubMed ID: 36881059
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes.
Konishi H; Shirakawa J; Arai M; Terauchi Y
Endocr J; 2019 Jun; 66(6):571-574. PubMed ID: 30944270
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Sci Rep; 2022 Sep; 12(1):15619. PubMed ID: 36114412
[TBL] [Abstract][Full Text] [Related]
14. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract][Full Text] [Related]
15. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
16. [A Case of Renal Cell Carcinoma with High Everolimus Blood Concentrations and Hyperglycemia Due to Everolimus-Induced Hepatic Dysfunction].
Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
Gan To Kagaku Ryoho; 2017 Jan; 44(1):87-89. PubMed ID: 28174388
[TBL] [Abstract][Full Text] [Related]
17. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.
Kanbayashi Y; Tsuchiya E; Shimizu T; Uchida M
Daru; 2024 Jun; 32(1):279-287. PubMed ID: 38671257
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
[TBL] [Abstract][Full Text] [Related]
20. [Spontaneous Remission of Everolimus-Induced Interstitial Lung Disease in Metastatic Renal Cell Carcinoma : An Autopsy Case Report].
Kurokawa M; Naito S; Ichiyanagi O; Kabasawa T; Kurota Y; Sakurai T; Nishida H; Kawazoe H; Kato T; Nagaoka A; Yamakawa M; Tsuchiya N
Hinyokika Kiyo; 2017 Sep; 63(9):377-380. PubMed ID: 28992668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]